To include your compound in the COVID-19 Resource Center, submit it here.

Merck's evobrutinib meets in Phase IIb for MS

Merck KGaA (Xetra:MRK) said evobrutinib (M2951, MSC2364447C) met the primary endpoints of reducing the total number of

Read the full 173 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE